Pfizer is asking the FDA to issue an Emergency Use Authorization to allow Paxlovid to be used for the treatment of high-risk patients who have mild to moderate COVID-19.
According to Pfizer, similar results were seen in patients who got the pill within five days of onset of their COVID-19 symptoms. No deaths were reported in the group that took Paxlovid.
The analysis included data from more than 1,200 people in North and South America, Europe, Africa and Asia who were enrolled in the clinical trial by Sept.
As of Tuesday, officials have reported 47.2 million COVID-19 cases nationwide, resulting in more than 765,000 deaths, according to a tally from Johns Hopkins University.
By using this website, you accept the terms of our Visitor Agreement and Privacy Policy, and understand your options regarding Ad Choices.